{"transactions":[{"id":786807,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-08T20:59:47.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":4185,"derivative":{"underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001682852-26-000088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000088/form4.xml","form_type":"4"}},{"id":786806,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:59:47.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":6454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":6454,"derivative":{"exercise_price":48.79,"expiration_date":"2036-05-06","underlying":"Common Stock","underlying_shares":6454},"source":{"system":"sec-edgar","filing":"0001682852-26-000088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000088/form4.xml","form_type":"4"}},{"id":793845,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-05-04T20:48:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":12174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 30, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12174},"source":{"system":"sec-edgar","filing":"0001682852-26-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000064/form4.xml","form_type":"4"}},{"id":793844,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-04T20:48:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":12174,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":32781,"source":{"system":"sec-edgar","filing":"0001682852-26-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000064/form4.xml","form_type":"4"}},{"id":815899,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:23:31.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date."}],"balance_after":20400,"derivative":{"exercise_price":30.78,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001365343-26-000003","document":"form4-04032026_080427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000136534326000003/form4-04032026_080427.xml","form_type":"4"}},{"id":1162460,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-01T20:33:15.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":12174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":12174,"derivative":{"underlying":"Common Stock","underlying_shares":12174},"source":{"system":"sec-edgar","filing":"0001127602-25-012941","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760225012941/form4.xml","form_type":"4"}},{"id":1162459,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T20:33:15.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":6378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service."}],"balance_after":6378,"derivative":{"exercise_price":28.54,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":6378},"source":{"system":"sec-edgar","filing":"0001127602-25-012941","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760225012941/form4.xml","form_type":"4"}},{"id":1524794,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-07T21:02:14.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":7557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":7557,"derivative":{"exercise_price":122.13,"expiration_date":"2034-05-06","underlying":"Common Stock","underlying_shares":7557},"source":{"system":"sec-edgar","filing":"0001127602-24-014472","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760224014472/form4.xml","form_type":"4"}},{"id":1855587,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T23:00:36.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting."}],"balance_after":41000,"derivative":{"exercise_price":2.54,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001209191-23-037188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000120919123037188/doc4.xml","form_type":"4"}},{"id":1902785,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-05T20:14:31.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":6134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":6134,"derivative":{"exercise_price":130.14,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":6134},"source":{"system":"sec-edgar","filing":"0001127602-23-014680","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760223014680/form4.xml","form_type":"4"}},{"id":2160010,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-25","kind":"other","acquired":true,"shares":138500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FN TALS LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":386932,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160009,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-25","kind":"other","acquired":false,"shares":138500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160008,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-21","kind":"purchase","acquired":true,"shares":36500,"price":3.72,"value":135780.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":138500,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160007,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-21","kind":"other","acquired":true,"shares":248432,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FN TALS LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":248432,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160006,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-21","kind":"other","acquired":false,"shares":248432,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Francois Nader 2020 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"This amendment is being filed solely to correct the number of shares reported by the Francois Nader 2020 Trust, which was incorrectly reported due to an administrative error."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person''s spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":147255,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160005,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-20","kind":"purchase","acquired":true,"shares":52000,"price":3.62,"value":188240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":102000,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2160004,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-13T20:27:51.000Z","date":"2022-07-19","kind":"purchase","acquired":true,"shares":50000,"price":3.52,"value":176000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-22-030924","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322030924/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-25"}},{"id":2202612,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-25","kind":"other","acquired":true,"shares":138500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FN TALS LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":386932,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202611,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-25","kind":"other","acquired":false,"shares":138500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202610,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-21","kind":"purchase","acquired":true,"shares":36500,"price":3.72,"value":135780.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":138500,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202609,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-21","kind":"other","acquired":true,"shares":248432,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FN TALS LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":248432,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202608,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-21","kind":"other","acquired":false,"shares":248432,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Francois Nader 2020 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person's spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":87735,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202607,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-20","kind":"purchase","acquired":true,"shares":52000,"price":3.62,"value":188240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":102000,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2202606,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:35:38.000Z","date":"2022-07-19","kind":"purchase","acquired":true,"shares":50000,"price":3.52,"value":176000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-22-026684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322026684/doc4.xml","form_type":"4"}},{"id":2233781,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T22:14:55.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":14501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting."}],"balance_after":14501,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":14501},"source":{"system":"sec-edgar","filing":"0000899243-22-022249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924322022249/doc4.xml","form_type":"4"}},{"id":2273550,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-12T20:22:00.000Z","date":"2022-05-10","kind":"exercise","acquired":false,"shares":23100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable."}],"balance_after":16620,"derivative":{"exercise_price":18.87,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":23100},"source":{"system":"sec-edgar","filing":"0001127602-22-014263","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222014263/form4.xml","form_type":"4"}},{"id":2273549,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-12T20:22:00.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":3196,"price":136.1,"value":434975.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover the payment of the exercise price of the option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.10 to $136.17. Full information regarding the number of shares sold at each separate price can be\nfurnished to the SEC staff upon request."}],"balance_after":20607,"source":{"system":"sec-edgar","filing":"0001127602-22-014263","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222014263/form4.xml","form_type":"4"}},{"id":2273548,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-12T20:22:00.000Z","date":"2022-05-10","kind":"exercise","acquired":true,"shares":23100,"price":18.87,"value":435897.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022."}],"balance_after":23803,"source":{"system":"sec-edgar","filing":"0001127602-22-014263","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222014263/form4.xml","form_type":"4"}},{"id":2286510,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-02T20:40:55.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":5415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":5415,"derivative":{"exercise_price":142.52,"underlying":"Common Stock","underlying_shares":5415},"source":{"system":"sec-edgar","filing":"0001127602-22-012857","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012857/form4.xml","form_type":"4"}},{"id":2286509,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-05-02T20:40:55.000Z","date":"2022-04-28","kind":"exercise","acquired":false,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award vested in full on April 28, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":703},"source":{"system":"sec-edgar","filing":"0001127602-22-012857","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012857/form4.xml","form_type":"4"}},{"id":2286508,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-02T20:40:55.000Z","date":"2022-04-28","kind":"exercise","acquired":true,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":703,"source":{"system":"sec-edgar","filing":"0001127602-22-012857","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760222012857/form4.xml","form_type":"4"}},{"id":2469571,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T21:05:23.000Z","date":"2021-12-15","kind":"gift","acquired":false,"shares":59520,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Francois Nader 2020 Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held in a trust for the benefit of the reporting person's spouse and child. The reporting person's spouse and child are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":336167,"source":{"system":"sec-edgar","filing":"0000899243-21-048599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365343/000089924321048599/doc4.xml","form_type":"4"}},{"id":2500505,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":3222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500504,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":8185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500503,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500502,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.48,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500501,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.2,"underlying":"Common Stock","underlying_shares":576},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500500,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500499,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":34.14,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500498,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":30.17,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500497,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":27.97,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2500496,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T09:06:36.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":6749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142272","document":"tm2133601-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142272/tm2133601-6_4seq1.xml","form_type":"4"}},{"id":2626543,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-07-23T16:36:17.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":13921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the \"Merger Consideration\").  Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899866-21-000065","document":"wf-form4_162707256224916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000065/wf-form4_162707256224916.xml","form_type":"4"}},{"id":2699678,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-05-24T16:30:45.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director."}],"balance_after":13921,"source":{"system":"sec-edgar","filing":"0000899866-21-000043","document":"wf-form4_162188822137068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000043/wf-form4_162188822137068.xml","form_type":"4"}},{"id":2699677,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-05-24T16:30:45.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date."}],"balance_after":13248,"source":{"system":"sec-edgar","filing":"0000899866-21-000043","document":"wf-form4_162188822137068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000043/wf-form4_162188822137068.xml","form_type":"4"}},{"id":2734536,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-04-30T20:10:44.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":703,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":703},"source":{"system":"sec-edgar","filing":"0001127602-21-014773","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760221014773/form4.xml","form_type":"4"}},{"id":2734535,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-30T20:10:44.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":4081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":4081,"derivative":{"exercise_price":178.68,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":4081},"source":{"system":"sec-edgar","filing":"0001127602-21-014773","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760221014773/form4.xml","form_type":"4"}},{"id":2885150,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T18:26:10.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":3222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":3222,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001179110-21-001106","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001106/edgar.xml","form_type":"4"}},{"id":2885149,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T18:26:10.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6749,"source":{"system":"sec-edgar","filing":"0001179110-21-001106","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001106/edgar.xml","form_type":"4"}},{"id":2895493,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T17:12:15.000Z","date":"2021-01-22","kind":"disposition_to_issuer","acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":16.98,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-005429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005429/doc4.xml","form_type":"4"}},{"id":2895492,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T17:12:15.000Z","date":"2021-01-22","kind":"disposition_to_issuer","acquired":false,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":10.26,"underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-21-005429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005429/doc4.xml","form_type":"4"}},{"id":2895491,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T17:12:15.000Z","date":"2021-01-22","kind":"disposition_to_issuer","acquired":false,"shares":133447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.81,"underlying":"Common Stock","underlying_shares":133447},"source":{"system":"sec-edgar","filing":"0001209191-21-005429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005429/doc4.xml","form_type":"4"}},{"id":2895490,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-26T17:12:15.000Z","date":"2021-01-22","kind":"other","acquired":false,"shares":23747,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Merger Agreement, these shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive (i) $22.50 per share of common stock, net to the seller in cash, without interest (the \"Closing Amount\"), plus (ii) one contingent value right per share (a \"CVR\"), which shall represent the right to receive certain consideration based on the achievement of net sales milestones."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Jesra Ventures LLC (the \"LLC\"). The Reporting Person is a manager and a member of the LLC and, as such, may be deemed to share voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of those shares owned by the LLC, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-005429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005429/doc4.xml","form_type":"4"}},{"id":3104379,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T18:36:12.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 17, 2021 and (ii) the date immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":17000,"derivative":{"exercise_price":16.98,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-20-038055","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919120038055/doc4.xml","form_type":"4"}},{"id":3146175,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-05-18T17:14:09.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director."}],"balance_after":11286,"source":{"system":"sec-edgar","filing":"0000899866-20-000045","document":"wf-form4_158983643012166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000045/wf-form4_158983643012166.xml","form_type":"4"}},{"id":3146174,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-05-18T17:14:09.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":3468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the earlier of (i) the first anniversary of the grant date and (ii) the date of the 2021 Annual Shareholder Meeting."}],"balance_after":10345,"source":{"system":"sec-edgar","filing":"0000899866-20-000045","document":"wf-form4_158983643012166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000045/wf-form4_158983643012166.xml","form_type":"4"}},{"id":3166500,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-30T21:33:32.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":18270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":18270,"derivative":{"exercise_price":46.37,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":18270},"source":{"system":"sec-edgar","filing":"0001127602-20-014881","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760220014881/form4.xml","form_type":"4"}},{"id":3302761,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-24T17:37:15.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":8185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":8185,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001179110-20-000773","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000773/edgar.xml","form_type":"4"}},{"id":3302760,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T17:37:15.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":1377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5127,"source":{"system":"sec-edgar","filing":"0001179110-20-000773","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000773/edgar.xml","form_type":"4"}},{"id":3345335,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T23:25:48.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":17889,"price":18.87,"value":337565.43,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service."}],"balance_after":17889,"derivative":{"exercise_price":18.87,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":17889},"source":{"system":"sec-edgar","filing":"0001127602-19-034834","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760219034834/form4.xml","form_type":"4"}},{"id":3345334,"issuer":{"id":2025,"kind":"organization","name":"Moderna, Inc.","symbol":"MRNA"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T23:25:48.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":39720,"price":18.87,"value":749516.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will be fully vested and exercisable on December 10, 2020."}],"balance_after":39720,"derivative":{"exercise_price":18.87,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":39720},"source":{"system":"sec-edgar","filing":"0001127602-19-034834","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1682852/000112760219034834/form4.xml","form_type":"4"}},{"id":3478783,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-06-25T18:51:04.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":23747,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into the same number of shares of the Company's Common Stock upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the same number of shares of the Company's Common Stock upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the same number of shares of the Company's Common Stock upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the same number of shares of the Company's Common Stock upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Jesra Ventures LLC (the \"LLC\"). The Reporting Person is a manager and a member of the LLC and, as such, may be deemed to share voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of those shares owned by the LLC, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23747},"source":{"system":"sec-edgar","filing":"0001209191-19-039015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919119039015/doc4.xml","form_type":"4"}},{"id":3478782,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T18:51:04.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":23747,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the same number of shares of the Company's Common Stock upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Jesra Ventures LLC (the \"LLC\"). The Reporting Person is a manager and a member of the LLC and, as such, may be deemed to share voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of those shares owned by the LLC, except to the extent of his pecuniary interest therein."}],"balance_after":23747,"source":{"system":"sec-edgar","filing":"0001209191-19-039015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919119039015/doc4.xml","form_type":"4"}},{"id":3522265,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-05-17T16:37:50.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":2726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date."}],"balance_after":6877,"source":{"system":"sec-edgar","filing":"0000899866-19-000072","document":"wf-form4_155812545529519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000072/wf-form4_155812545529519.xml","form_type":"4"}},{"id":3683704,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-29T17:44:30.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-19-001058","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019001058/edgar.xml","form_type":"4"}},{"id":3683703,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-29T17:44:30.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001179110-19-001058","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019001058/edgar.xml","form_type":"4"}},{"id":3937737,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-05-11T16:12:24.000Z","date":"2018-05-09","kind":"grant","acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date."}],"balance_after":4151,"source":{"system":"sec-edgar","filing":"0000899866-18-000091","document":"wf-form4_152606948345235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000091/wf-form4_152606948345235.xml","form_type":"4"}},{"id":4014536,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-03-05T17:18:45.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-003499","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911018003499/edgar.xml","form_type":"4"}},{"id":4014535,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-05T17:18:45.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001179110-18-003499","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911018003499/edgar.xml","form_type":"4"}},{"id":4148200,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-11-30T16:12:39.000Z","date":"2017-11-29","kind":"grant","acquired":true,"shares":1977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date."}],"balance_after":1977,"source":{"system":"sec-edgar","filing":"0000899866-17-000181","document":"wf-form4_151207634571689.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000181/wf-form4_151207634571689.xml","form_type":"4"}},{"id":4386113,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-14T18:18:55.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-17-004593","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911017004593/edgar.xml","form_type":"4"}},{"id":4386112,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":48710,"kind":"person","name":"Nader Francois","position":1,"cik":"0001365343","reported_name":"Nader Francois","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-14T18:18:55.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001179110-17-004593","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911017004593/edgar.xml","form_type":"4"}}]}